Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cell therapy targets a marker on myeloma cells

NCT ID NCT04649073

Cure Sponsor: Otsuka Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers are testing a cell therapy called OPC-415 in adults with multiple myeloma that has come back or stopped responding to standard treatments. Participants must have the MMG49 antigen on their cancer cells and have already tried at least two prior regimens. The trial measures safety and side effects in its first stage, then tracks how many patients see their cancer shrink in the second stage.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
OPC-415, an experimental cell therapy that targets the MMG49 antigen on myeloma cells
What this could lead to
If it works, this could offer a new treatment option for people whose multiple myeloma has returned after several prior therapies.
What could go wrong
This is a very small, early-stage trial with no control group, so safety and benefit are still unproven. Cell therapies can cause serious immune reactions, and the results may not apply to a wider group of patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

11 people

The number who actually took part.

Started

Feb 2021

Finished

Apr 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged between 20 and 80 (75 for the phase 1 part) years, both inclusive, at the time of consent * Patients with a definitive diagnosis of active multiple myeloma * Patients who have had 2 or more prior regimens (including all proteasome inhibitors, immunomodulators, and anti-CD38 antibody) * Patients with relapsed and/or refractory Multiple Myeloma * Patients who are positive for MMG49 antigen * Patients with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. Those with an ECOG-PS score of 2 due solely to MM bone lesions can be enrolled * Patients who are expected to survive for at least 3 months Exclusion Criteria: * Patients who are scheduled to receive high-dose chemotherapy in combination with autologous stem cell transplantation as the next treatment. * Patients who have other active double/multiple cancers * Patients on continuous and systemic (oral or intravenous) medication with corticosteroids or other immunosuppressive agents * Patients with graft-versus-host disease that requires treatment. * Patients who underwent a highly invasive and extensive surgical procedure within 2 weeks. * Patients who previously underwent allogeneic stem cell transplantation or organ transplantation. * Patients who underwent autologous stem cell transplantation within 90 days. * Patients with systemic amyloidosis (except localized amyloidosis without organ derangement) or plasma cell leukemia. * Patients with prior or current central nerve involvement in MM. * Patients whose best ever response to MM treatment is PD. * Patients who previously received gene therapy or cell therapy (except hematopoietic stem cell transplantation). * Pregnant women, nursing mothers, or women with a positive pregnancy test.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma (MM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma (MM)

Contacts and locations

Locations

  • Japanese Red Cross Medical Center

    Shibuya-ku, Japan

  • Nagoya City University Hospital

    Nagoya, Japan

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan

  • Osaka University Hospital

    Suita-shi, Japan

  • Sapporo Medical University Hospital

    Sapporo, Japan

  • Tohoku University Hospital

    Sendai, Japan

  • Tokai University Hospital

    Isehara-shi, Japan

  • Yamagata University Hospital

    Yamagata, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.